Assuming data is required, the following results were found.

  • Genentech to Present Pivotal Data for Satralizumab in Neuromyelitis Optica Spectrum Disorder and Six-year Ocrevus (Ocrelizumab) Data in Multiple Sclerosis at ECTRIMS

    reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis optica spectrum disorder (NMOSD)New data provide insights into neurofilament light chain (NfL) levels as a potential biomarker for predicting multiple sclerosis (MS)...

    https://mschristian.org/index.php/blog/genentech-to-present-pivotal-data-for-satralizumab-in-neuromyelitis-optica-spectrum-disorder-and-six-year-ocrevus-ocrelizumab-data-in-multiple-sclerosis-at-ectrims
  • #ECTRIMS2019 – Tysabri During Pregnancy and After Delivery Seems Safe, Reduces Relapse Risk, Study Finds

    especially second-line treatments which are usually used for highly active MS women,” Landi said. One problem is the lack of data that can elucidate the risks, and guide therapy choices before, during, and after pregnancy. In particular, there is a lack...

    https://mschristian.org/index.php/blog/ectrims2019-tysabri-during-pregnancy-and-after-delivery-seems-safe-reduces-relapse-risk-study-finds
  • Genentech Presents New Six-Year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and Continuation of Treatment Reduced Disability Progression in Multiple Sclerosis

    treatment – – More than 120,000 people have been treated with Ocrevus globally, in clinical trial and real-world settings; data continue to show a consistent and favorable benefit-risk profile – Genentech, a member of the Roche Group (SIX: RO, ROG;...

    https://mschristian.org/index.php/blog/genentech-presents-new-six-year-ocrevus-ocrelizumab-data-which-showed-that-earlier-initiation-and-continuation-of-treatment-reduced-disability-progression-in-multiple-sclerosis
  • Fooling nerve cells into acting normal

    Discovery could inform future studies related to spinal cord injuries, multiple sclerosis and epilepsy Date:Source:University of Missouri-ColumbiaSummary:Scientists have discovered that a neuron's own electrical signal, or voltage, can indicate whether...

    https://mschristian.org/index.php/blog/fooling-nerve-cells-into-acting-normal
  • Capsule Technologies Launches Next Generation Clinical Computing Hub - P&T Community

    computing hub. Building on its predecessors' market leading capabilities which include secure capture of medical device data, touchscreen with local data processing and caching, secure point of care rapid authentication and patient association and...

    https://mschristian.org/index.php/blog/capsule-technologies-launches-next-generation-clinical-computing-hub-p-t-community
  • International MS Genetics Consortium Confirms 233 MS-Related Gene Variations in Largest Study to Date

    2019 SUMMARY:The International MS Genetics Consortium (IMSGC) has published the largest MS genetics study to date, analyzing data from 47,429 people with MS and 68,374 individuals without MS.They confirmed 233 variations in the human genome that...

    https://mschristian.org/index.php/blog/international-ms-genetics-consortium-confirms-233-ms-related-gene-variations-in-largest-study-to-date
  • Siponimod Delays Time to Wheelchair in Secondary Progressive MS - Neurology Times

    The oral selective sphingosine-1-phosphate receptor modulator significantly delayed time to wheelchair dependence.1 The data were presented by Patrick Vermersch, MD, PhD, vice-dean, faculty of medicine, University of Lille, at ECTRIMS 2019, September...

    https://mschristian.org/index.php/blog/siponimod-delays-time-to-wheelchair-in-secondary-progressive-ms-neurology-times
  • #ECTRIMS2019 - Mayzent's Benefits for MS Patients a 'Key Question,' Says EXPAND's Principal Investigator - Multiple Sclerosis News Today

    The most recent data continue to support Mayzent‘s (siponimod) benefits and provide more insights on how this therapy can make a difference for those with relapsing forms of multiple sclerosis (MS) — in particular, data showing the therapy lowers the...

    https://mschristian.org/index.php/blog/ectrims2019-mayzent-s-benefits-for-ms-patients-a-key-question-says-expand-s-principal-investigator-multiple-sclerosis-news-today
  • Vaccinations do not raise risk of multiple sclerosis

    that vaccinations increase the likelihood of MS. Researchers at the Technical University of Munich (TUM) in Germany studied data on more than 200,000 people who were representative of the general population. The data came from the Bavarian Association...

    https://mschristian.org/index.php/blog/vaccinations-do-not-raise-risk-of-multiple-sclerosis
  • MSCristian Privacy Notice

    the website, how it is used and with whom it may be shared. What choices are available to you regarding the use of your data. The security procedures in place to protect the misuse of your information. How you can correct any inaccuracies in the...

    https://mschristian.org/index.php/articles/site-info/7771-mscristian-privacy-notice
  • Disability progression in multiple sclerosis linked to income, education

    from the University of British Columbia. UBC researchers, along with colleagues in Wales, compared population health data across several measures of socioeconomic status, and found that lower neighbourhood-level income and educational attainment was...

    https://mschristian.org/index.php/blog/disability-progression-in-multiple-sclerosis-linked-to-income-education
  • #ECTRIMS2019 – Data Shows Ublituximab’s Long-term Safety in Relapsing MS, TG Therapeutics Announced

    diseases like MS, lupus and rheumatoid arthritis. Ublituximab (TGTX-1101) research in RMS TG Therapeutics released early data from a Phase 2 study (NCT0273877) assessing ublitiximab’s safety and efficacy in RMS patients in January 2017. The first part...

    https://mschristian.org/index.php/blog/ectrims2019-data-shows-ublituximab-s-long-term-safety-in-relapsing-ms-tg-therapeutics-announced
  • Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress - BioSpace

    profile and early findings of potential efficacy for people living with progressive MS, as shown in our Phase 1a study data presented at ECTRIMS in September,” said AJ Joshi, MD, Senior Vice President and Chief Medical Officer of Atara Biotherapeutics....

    https://mschristian.org/index.php/blog/atara-biotherapeutics-announces-third-quarter-2019-financial-results-and-recent-clinical-operational-and-strategic-progress-biospace
  • Trending News Today: FDA Accepts NDA for Topical Rosacea Treatment - Pharmacy Times

    on their treatment, The American Journal of Managed Care reported. According to the article, the study researchers analyzed data from a total of 6421 patients with MS, with a comparator cohort of 42,645 individuals. Overall, patients with MS on...

    https://mschristian.org/index.php/blog/trending-news-today-fda-accepts-nda-for-topical-rosacea-treatment-pharmacy-times
  • Following vapers

    go through stringent age verification checks that included facial recognition and two-step background check with third-party databases. Juul’s C1 device will allow users to monitor how many puffs they take a day, as well as locate their vape if they...

    https://mschristian.org/index.php/blog/following-vapers
  • Research Project 3TR To Use Breath Biopsy, Improve Immune-mediated Disease Management - Technology Networks

    pharma, covering 15 European countries. Under the initiative, 3TR will have access to an unprecedented quantity of clinical data and samples of more than 50,000 patients across 50 ongoing and new clinical trials, ultimately aiming to discover and verify...

    https://mschristian.org/index.php/blog/research-project-3tr-to-use-breath-biopsy-improve-immune-mediated-disease-management-technology-networks
  • Anokion Presents New Data Describing Transformative Therapeutic Approach for Treatment of Multiple Sclerosis at ECTRIMS Congress - streetinsider.com

    CAPTCHA. You reached this page when attempting to access https://www.streetinsider.com/Business Wire/Anokion Presents New Data Describing Transformative Therapeutic Approach for Treatment of Multiple Sclerosis at ECTRIMS Congress/15912284.html from...

    https://mschristian.org/index.php/blog/anokion-presents-new-data-describing-transformative-therapeutic-approach-for-treatment-of-multiple-sclerosis-at-ectrims-congress-streetinsider-com
  • #ECTRIMS2019 - Are Injectables Inappropriate for Active Relapsing MS? - Multiple Sclerosis News Today

    audience voted to name the winning debater through Twitter. Older injectable use is inapproppriate Kobelt argued that ample data from both clinical trials and real-world practice favor newer disease-modifying treatments (DMTs). DMTs used as second-line...

    https://mschristian.org/index.php/blog/ectrims2019-are-injectables-inappropriate-for-active-relapsing-ms-multiple-sclerosis-news-today
  • Biogen Strengthens MS & SMA Portfolio as Competition Lurks - Yahoo Finance

    fibrosis or IPF), dapirolizumab pegol (active systemic lupus erythematosus [SLE], among others. In 2019/2020, important data readouts are expected across clinical programs in MS, Progressive supranuclear palsy (PSP) lupus, epilepsy, Parkinson’s disease...

    https://mschristian.org/index.php/blog/biogen-strengthens-ms-sma-portfolio-as-competition-lurks-yahoo-finance
  • Can Anti-TNF Drugs Reduce Alzheimer's Risk?

    in a manuscript on the preprint server medRxiv. These findings show the power of combining expert knowledge with big data analytics, Xu said. "Retrospective clinical studies using very large databases of patient electronic health records have high...

    https://mschristian.org/index.php/blog/can-anti-tnf-drugs-reduce-alzheimer-s-risk

Results 1 - 20 of 58
 
 

Follow Us on Twitter

Follow Us On Twitter - Image